Condition: Phenylketonuria (PKU) · Sponsor: BioMarin Pharmaceutical
This is a 10-year multi-center, global, observational study to further characterize the safety profile of pegvaliase, including hypersensitivity reactions, long-term safety and tolerability, and the effectiveness of the additional risk minimization measures (aRMMs) (European Union (EU) only) in subjects receiving pegvaliase for the treatment of PKU. Subjects for whom a clinical decision has been made that they will receive pegvaliase to treat their PKU within 30 days following the date of enrollment (incident-users) or have previously started treatment with pegvaliase at the date of enrollment (prevalent-users) are eligible for participation in this study.
This description comes directly from the study's public registry record.
165-501 Program Director · 1-800-983-4587 · medinfo@bmrn.com
Medical Director, MD · 1-800-983-4587 · medinfo@bmrn.com
Always discuss trial participation with your own doctor first.
| University of Colorado | Aurora, Colorado, United States | Recruiting |
| Emory University | Atlanta, Georgia, United States | Recruiting |
| Northwestern University | Chicago, Illinois, United States | Recruiting |
| Indiana University School of Medicine | Indianapolis, Indiana, United States | Recruiting |
| Tulane University Medical Center | New Orleans, Louisiana, United States | Recruiting |
| Boston Children's Hospital | Boston, Massachusetts, United States | Recruiting |
| Oregon Health and Science University | Portland, Oregon, United States | Recruiting |
| University of Pittsburgh Medical Center | Pittsburgh, Pennsylvania, United States | Recruiting |
| Vanderbilt University Medical School | Nashville, Tennessee, United States | Recruiting |
| University of Texas Southwestern Medical Center | Dallas, Texas, United States | Recruiting |
| University of Utah | Salt Lake City, Utah, United States | Recruiting |
| Medical College of Wisconsin | Milwaukee, Wisconsin, United States | Recruiting |
+ 14 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05813678